Last month, the United States Food and Drug Administration (FDA) approved a new wearable device for treating pancreatic cancer. This device, called Optune Pax, sends alternating electric fields to the ...

The latest Windows 11 preview build introduces the ability to specify a custom user directory for your account, something both macOS and Linux have supported for decades. When you purchase through ...

Burner accounts on social media sites can increasingly be analyzed to identify the pseudonymous users who post to them using AI in research that has far-reaching consequences for privacy on the ...

Optune Lua is a wearable, portable medical device that produces alternating electric fields known as Tumor Treating Fields (TTFields), which are delivered through non-invasive, wearable arrays.

That's up from 700 million users in September last year and more than doubled from where it was last year. TV and home video editor Ty Pendlebury joined CNET Australia in 2006, and moved to New York ...

Chief Executive Officer Leonard said, "we are committed to returning the company to steady growth," highlighting a new phase of public messaging and performance expectations. Full-year net loss and ...

Image source: The Motley Fool. NovoCure (NASDAQ:NVCR) reported its highest annual net revenue to date, driven by international patient growth and new product launches. The company communicated its ...

Carolyn Gusoff has covered some of the most high profile news stories in the New York City area and is best known as a trusted, tenacious, consistent and caring voice of Long Island's concerns. For ...

In a phase 3 trial, Optune Pax plus gem/nab-pac significantly improved median overall survival to 16.2 months vs 14.2 months with chemotherapy alone. The Food and Drug Administration (FDA) has ...

Novocure NVCR recently announced the FDA approval for its portable therapeutic device, Optune Pax, for treating adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and ...